Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial - Camidge, D; Kim, H; Ahn, M (J Clin Oncol, 2020)
et al.